Schnitzer J E, Oh P
Department of Medicine and Pathology, University of California-San Diego School of Medicine, La Jolla 92093-0651.
J Biol Chem. 1994 Feb 25;269(8):6072-82.
Specific albumin binding to the surface of endothelium initiates its transcytosis across continuous endothelium via noncoated plasmalemmal vesicles. Past work has identified several putative albumin-binding proteins (SPARC, gp60, gp30, and gp18). In this study, we examined the specific role of these proteins in the binding of bovine serum albumin (BSA) to endothelium. The 60-kDa albumin-binding protein (gp60, now called albondin) was purified from cultured rat microvascular endothelial cells for antibody production. Anti-albondin antibodies (alpha gp60) specifically recognized albondin expressed by rat, bovine, and human endothelial cells (EC). alpha gp60 and unlabeled native BSA inhibited 125I-BSA binding to confluent EC monolayers and to both albondin and SPARC extracts immobilized on filters. Modification of BSA by maleic anhydride treatment (Mal-BSA) or by surface adsorption to colloidal gold particles (A-Au) renders the ligand specific for gp30 and gp18 while eliminating its ability to inhibit 125I-BSA binding to EC and to both albondin and SPARC extracts. Mal-BSA and A-Au interacted with EC via distinct binding sites not recognizing native BSA. EC internalization of 125I-BSA is inhibited by unlabeled BSA and alpha gp60 IgG but not nonimmune IgG, Mal-BSA, or A-Au. Conversely, internalization of modified BSA is inhibited by unlabeled modified BSA but not BSA or alpha gp60 IgG. Specific 125I-BSA transendothelial transport in rat lungs perfused in situ and for EC monolayers in vitro is inhibited (> or = 90%) by unlabeled BSA and alpha gp60 IgG but not nonimmune IgG and Mal-BSA. No specific transport of 125I-Mal-BSA is detected across bovine lung microvascular endothelial cell monolayers, only paracellular and/or fluid-phase transport. Low temperatures reduce BSA transport by 5-fold and Mal-BSA by 2-fold. Interestingly, 3-fold more native BSA is transported than Mal-BSA at 37 degrees C, whereas at 8-10 degrees C they are nearly equal, suggesting facilitation of BSA transport. Cumulatively, it appears that gp30 and gp18 mediate the binding, endocytosis, and degradation of modified albumins, whereas albondin mediates native albumin binding which significantly enhances its transcytosis and capillary permeability.
特异性白蛋白与内皮表面结合,通过无被质膜小泡启动其跨连续内皮的转胞吞作用。过去的研究已经鉴定出几种假定的白蛋白结合蛋白(SPARC、gp60、gp30和gp18)。在本研究中,我们研究了这些蛋白在牛血清白蛋白(BSA)与内皮结合中的具体作用。从培养的大鼠微血管内皮细胞中纯化出60 kDa的白蛋白结合蛋白(gp60,现称为albondin)用于制备抗体。抗albondin抗体(α gp60)能特异性识别大鼠、牛和人内皮细胞(EC)表达的albondin。α gp60和未标记的天然BSA抑制125I-BSA与汇合的EC单层以及固定在滤膜上的albondin和SPARC提取物的结合。用马来酸酐处理(Mal-BSA)或通过表面吸附到胶体金颗粒(A-Au)对BSA进行修饰,使配体对gp30和gp18具有特异性,同时消除其抑制125I-BSA与EC以及albondin和SPARC提取物结合的能力。Mal-BSA和A-Au通过不识别天然BSA的不同结合位点与EC相互作用。125I-BSA的EC内化受到未标记的BSA和α gp60 IgG的抑制,但不受非免疫IgG、Mal-BSA或A-Au的抑制。相反,修饰后BSA的内化受到未标记的修饰后BSA的抑制,但不受BSA或α gp60 IgG的抑制。未标记的BSA和α gp60 IgG可抑制原位灌注的大鼠肺以及体外EC单层中特异性125I-BSA的跨内皮转运(≥90%),但非免疫IgG和Mal-BSA则无此作用。在牛肺微血管内皮细胞单层中未检测到125I-Mal-BSA的特异性转运,只有旁细胞和/或液相转运。低温使BSA的转运降低5倍,使Mal-BSA的转运降低2倍。有趣的是,在37℃时,天然BSA的转运量比Mal-BSA多3倍,而在8-10℃时,二者几乎相等,这表明BSA的转运得到了促进。总的来说,似乎gp30和gp18介导修饰后白蛋白的结合、内吞和降解,而albondin介导天然白蛋白的结合,这显著增强了其转胞吞作用和毛细血管通透性。